Published in Proc Natl Acad Sci U S A on April 11, 2000
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J (2003) 3.58
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A (2003) 2.92
Protean PTEN: form and function. Am J Hum Genet (2002) 2.43
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J (2006) 2.16
PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab (2008) 1.92
Leptin regulates AMPA receptor trafficking via PTEN inhibition. J Neurosci (2010) 1.91
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene (2001) 1.78
PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A (2005) 1.67
PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A (2001) 1.62
Distinct claudins and associated PDZ proteins form different autotypic tight junctions in myelinating Schwann cells. J Cell Biol (2002) 1.60
Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface (2006) 1.53
Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J (2005) 1.47
Claudin family of proteins and cancer: an overview. J Oncol (2010) 1.42
Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell (2006) 1.38
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36
Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol (2010) 1.35
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J (2001) 1.29
PTEN function: the long and the short of it. Trends Biochem Sci (2014) 1.29
PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. EMBO J (2010) 1.26
PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol (2015) 1.24
Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell (2006) 1.21
Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein. Oncogene (2003) 1.20
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair. Br J Pharmacol (2007) 1.18
The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia (2003) 1.18
Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy. EMBO Mol Med (2012) 1.17
Regulation of T-cell responses by PTEN. Immunol Rev (2008) 1.15
Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res (2008) 1.14
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal (2009) 1.11
Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res (2010) 1.11
Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl Recept Signal (2008) 1.10
Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Cancer Res (2009) 1.08
Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer. Br J Cancer (2007) 1.08
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis. Elife (2013) 1.02
PTEN in liver diseases and cancer. World J Gastroenterol (2010) 0.97
Analysis of PTEN complex assembly and identification of heterogeneous nuclear ribonucleoprotein C as a component of the PTEN-associated complex. J Biol Chem (2009) 0.97
Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc. J Biol Chem (2010) 0.96
A new role for PTEN in regulating transient receptor potential canonical channel 6-mediated Ca2+ entry, endothelial permeability, and angiogenesis. J Biol Chem (2010) 0.95
Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders. Front Mol Neurosci (2014) 0.95
Proteomic and bioinformatic analysis of epithelial tight junction reveals an unexpected cluster of synaptic molecules. Biol Direct (2006) 0.94
Inhibition of the phosphatase PTEN protects mice against oleic acid-induced acute lung injury. Br J Pharmacol (2009) 0.94
Apoptosis regulator through modulating IAP expression (ARIA) controls the PI3K/Akt pathway in endothelial and endothelial progenitor cells. Proc Natl Acad Sci U S A (2011) 0.94
Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets (2014) 0.93
NHERFs, NEP, MAGUKs, and more: interactions that regulate PTEN. J Cell Biochem (2007) 0.93
MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis (2009) 0.93
Focus on PTEN Regulation. Front Oncol (2015) 0.93
Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J (2011) 0.93
IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis (2014) 0.92
The Akt-associated microRNAs. Cell Mol Life Sci (2012) 0.91
A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochem Biophys Res Commun (2006) 0.91
PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. Nat Neurosci (2016) 0.90
The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep (2016) 0.90
S-SCAM/MAGI-2 is an essential synaptic scaffolding molecule for the GluA2-containing maintenance pool of AMPA receptors. J Neurosci (2012) 0.90
Redox modifier genes and pathways in amyotrophic lateral sclerosis. Antioxid Redox Signal (2009) 0.88
PTEN modulators: a patent review. Expert Opin Ther Pat (2013) 0.88
Gene expression profile of androgen modulated genes in the murine fetal developing lung. Reprod Biol Endocrinol (2010) 0.88
Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment. Acta Pharmacol Sin (2011) 0.87
MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A (2014) 0.86
Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochem Biophys Res Commun (2009) 0.86
Cleavage of MAGI-1, a tight junction PDZ protein, by caspases is an important step for cell-cell detachment in apoptosis. Apoptosis (2007) 0.86
Nongenomic Mechanisms of PTEN Regulation. Int J Cell Biol (2012) 0.86
Disruption of occludin function in polarized epithelial cells activates the extrinsic pathway of apoptosis leading to cell extrusion without loss of transepithelial resistance. BMC Cell Biol (2009) 0.85
Identification of regulatory SNPs associated with genetic modifications in lung adenocarcinoma. BMC Res Notes (2015) 0.85
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene (2013) 0.85
Honey bee PTEN--description, developmental knockdown, and tissue-specific expression of splice-variants correlated with alternative social phenotypes. PLoS One (2011) 0.85
Evolution of metazoan cell junction proteins: the scaffold protein MAGI and the transmembrane receptor tetraspanin in the demosponge Suberites domuncula. J Mol Evol (2004) 0.85
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) (2015) 0.84
Mice lacking pten in osteoblasts have improved intramembranous and late endochondral fracture healing. PLoS One (2013) 0.81
Study of PTEN subcellular localization. Methods (2014) 0.80
Exosome-mediated delivery of the intrinsic C-terminus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesis. Mol Ther (2014) 0.80
PTEN, here, there, everywhere. Cell Death Differ (2013) 0.80
Molecular control of PtdIns(3,4,5)P3 signaling in neutrophils. EMBO Rep (2015) 0.79
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses. Virol J (2008) 0.79
Endosomal targeting of the phosphoinositide 3-phosphatase MTMR2 is regulated by an N-terminal phosphorylation site. J Biol Chem (2011) 0.79
Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J (2013) 0.78
Association analysis of genetic variants in the myosin IXB gene in acute pancreatitis. PLoS One (2013) 0.78
Drosophila MAGI interacts with RASSF8 to regulate E-Cadherin-based adherens junctions in the developing eye. Development (2015) 0.78
PTEN-Associated Complexes: An Overview. Curr Top Biochem Res (2010) 0.77
Role of TARP interaction in S-SCAM-mediated regulation of AMPA receptors. Channels (Austin) (2012) 0.76
Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes Dev (2015) 0.76
Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN. Sci Rep (2015) 0.76
Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. J Biol Chem (2015) 0.76
Engineering FKBP-Based Destabilizing Domains to Build Sophisticated Protein Regulation Systems. PLoS One (2015) 0.75
Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis. Elife (2017) 0.75
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Signaling through scaffold, anchoring, and adaptor proteins. Science (1997) 9.48
Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (1997) 8.16
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 6.62
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 5.92
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell (1991) 5.30
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science (1999) 4.36
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 4.19
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
A multivalent PDZ-domain protein assembles signalling complexes in a G-protein-coupled cascade. Nature (1997) 3.54
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol (1998) 3.51
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A (1997) 3.48
Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst (1999) 3.41
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science (1999) 3.15
Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature (1996) 3.11
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A (1999) 3.10
Akt/PKB localisation and 3' phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. Curr Biol (1999) 3.00
PDZ proteins organize synaptic signaling pathways. Cell (1998) 2.51
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins. J Biol Chem (1998) 1.82
Regulation of DLG localization at synapses by CaMKII-dependent phosphorylation. Cell (1999) 1.81
Clustering membrane proteins: It's all coming together with the PSD-95/SAP90 protein family. Cell (1996) 1.62
Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res (2000) 1.60
Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci (1998) 1.53
PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol (1998) 1.52
MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains. J Biol Chem (1997) 1.51
Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res (1996) 1.28
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol (1999) 1.27
Cloning and characterization of BAI-associated protein 1: a PDZ domain-containing protein that interacts with BAI1. Biochem Biophys Res Commun (1998) 1.22
Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer (1995) 1.12
Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem (2000) 1.10
Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer (1999) 1.09
Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas. Genes Chromosomes Cancer (1995) 0.93
Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase. Oncogene (1999) 0.89
Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet (1998) 0.85
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Are the problems of primary care in inner cities fact or fiction? Br Med J (Clin Res Ed) (1983) 7.90
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 4.56
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet (1998) 4.01
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Does the underprivileged area index work? Br Med J (Clin Res Ed) (1985) 3.35
Influence of cycloheximide (Actidione) upon pyrimidine nucleotide metabolism and rna synthesis in cocklebur leaf discs. Biochim Biophys Acta (1968) 3.22
High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol (1995) 3.04
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol (1990) 2.87
Oligomycin inhibition of phosphate uptake and ATP labeling in excised maize roots. Plant Physiol (1969) 2.76
Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab (1997) 2.71
An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol (1985) 2.68
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol (1995) 2.67
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Professional attitudes to patient participation groups: an exploratory study. J R Coll Gen Pract (1980) 2.56
Can some in-hospital cardio-respiratory arrests be prevented? A prospective survey. Resuscitation (1998) 2.44
Differentiation of normal and abnormal airway protection during swallowing using the penetration-aspiration scale. Dysphagia (1999) 2.44
Anthropoid origins. Science (1997) 2.41
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Extraction, separation, and quantitative estimation of soluble nucleotides and sugar phosphates in plant tissues. Anal Biochem (1966) 2.31
Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev (2001) 2.30
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem (1996) 2.29
Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry (2010) 2.21
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A (2007) 2.11
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A (1995) 2.10
Rapid immune response to influenza vaccination. Lancet (1993) 2.09
Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol (2001) 2.04
Differential rearing affects corpus callosum size and cognitive function of rhesus monkeys. Brain Res (1998) 2.04
Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. Clin Chem (1999) 2.01
An apology for AIDS. Lancet (1993) 2.00
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int (2001) 1.94
Etiology of acute conjunctivitis in children. J Pediatr (1981) 1.92
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci (2006) 1.92
Age effects on lingual pressure generation as a risk factor for dysphagia. J Gerontol A Biol Sci Med Sci (1995) 1.82
Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril (1990) 1.81
Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy. Histopathology (2008) 1.78
Learning rate for laparoscopic surgical skills on MIST VR, a virtual reality simulator: quality of human-computer interface. Ann R Coll Surg Engl (1999) 1.73
Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum (1995) 1.72
The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol (1995) 1.71
Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods (1990) 1.67
A clinical assessment of nine pregnancies obtained by in vitro fertilization and embryo transfer. Fertil Steril (1981) 1.67
Increased nuclease activity in cells treated with pppA2'p5'A2'p5' A. Proc Natl Acad Sci U S A (1979) 1.66
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des (2000) 1.63
Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet (2012) 1.58
Evidence based assessment. Br Dent J (1996) 1.57
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Bone marrow transplantation from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Xenotransplantation (2004) 1.56
A case control study of multiple myeloma at four nuclear facilities. Ann Epidemiol (2000) 1.55
Tricuspid replacement for acquired valve disease. Surg Gynecol Obstet (1966) 1.54
Clock mutations alter developmental timing in Drosophila. Heredity (Edinb) (1990) 1.53
Patient Profile: Inuvik General Hospital and Four Regional Nursing Stations, NWT. Can Fam Physician (1980) 1.53
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet (1998) 1.51
Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav (2006) 1.51
Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest (1997) 1.51
Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+. Circ Res (1998) 1.50
Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc Natl Acad Sci U S A (2000) 1.49
Monitoring Section 63 activities. J R Coll Gen Pract (1977) 1.49
Lymphocyte subpopulations in the blood of newborn infants. Clin Exp Immunol (1974) 1.48
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Incorporating patient preferences into randomized trials. J Clin Epidemiol (2000) 1.42
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
Intraarticular corticosteroid injections: should we rest the joints? Arthritis Care Res (1989) 1.41
Great vessel, cardiac chamber, and wall growth patterns in normal children. Circulation (1975) 1.41
Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses (2002) 1.40
Inhibition of leaf process by p-fluorophenylalanine during induction of flowering in the cocklebur. Plant Physiol (1966) 1.40
Multivariate analysis of glycosylated haemoglobin in insulin-treated diabetics. J R Soc Med (1985) 1.39
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology (2005) 1.37
Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science (1981) 1.37
Changes in hospital antibiotic therapy after a quality-of-use study. Lancet (1977) 1.33
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem (1996) 1.33
Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev (2001) 1.33
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol (2000) 1.31
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis (2003) 1.30
Synergies and coincidence requirements between NO, cGMP, and Ca2+ in the induction of cerebellar long-term depression. Neuron (1997) 1.29
Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J (2000) 1.28
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol (2000) 1.28
Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer (2001) 1.28
Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood (1998) 1.27
Surveillance of work-related asthma in selected U.S. states using surveillance guidelines for state health departments--California, Massachusetts, Michigan, and New Jersey, 1993-1995. MMWR CDC Surveill Summ (1999) 1.27